Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM, Harris DR, Rich K, Meyer WA 3rd, Read JS, Moye J Jr, Nugent RP, Korelitz J, Bethel J, Pahwa S. Mofenson LM, et al. Among authors: bethel j. AIDS. 1999 Jan 14;13(1):31-9. doi: 10.1097/00002030-199901140-00005. AIDS. 1999. PMID: 10207542 Clinical Trial.
Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Read JS, Rich KC, Korelitz JJ, Mofenson LM, Harris R, Moye JH Jr, Meyer WA 3rd, Pahwa SG, Bethel JW, Nugent RP. Read JS, et al. Among authors: bethel jw. Pediatr Infect Dis J. 2000 Jun;19(6):544-51. doi: 10.1097/00006454-200006000-00011. Pediatr Infect Dis J. 2000. PMID: 10877171 Clinical Trial.
Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM, Moye J Jr, Bethel J, Hirschhorn R, Jordan C, Nugent R. Mofenson LM, et al. Among authors: bethel j. JAMA. 1992 Jul 22-29;268(4):483-8. doi: 10.1001/jama.268.4.483. JAMA. 1992. PMID: 1352363 Clinical Trial.
Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM, Moye J Jr, Korelitz J, Bethel J, Hirschhorn R, Nugent R. Mofenson LM, et al. Among authors: bethel j. Pediatr Infect Dis J. 1994 Jun;13(6):477-84. doi: 10.1097/00006454-199406000-00003. Pediatr Infect Dis J. 1994. PMID: 8078734 Clinical Trial.
Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM, Bethel J, Moye J Jr, Flyer P, Nugent R. Mofenson LM, et al. Among authors: bethel j. J Acquir Immune Defic Syndr (1988). 1993 Oct;6(10):1103-13. J Acquir Immune Defic Syndr (1988). 1993. PMID: 8105072 Clinical Trial.
Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM, Korelitz J, Pelton S, Moye J Jr, Nugent R, Bethel J. Mofenson LM, et al. Among authors: bethel j. Clin Infect Dis. 1995 Nov;21(5):1175-81. doi: 10.1093/clinids/21.5.1175. Clin Infect Dis. 1995. PMID: 8589139 Clinical Trial.
The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM, Korelitz J, Meyer WA 3rd, Bethel J, Rich K, Pahwa S, Moye J Jr, Nugent R, Read J. Mofenson LM, et al. Among authors: bethel j. J Infect Dis. 1997 May;175(5):1029-38. doi: 10.1086/516441. J Infect Dis. 1997. PMID: 9129063 Clinical Trial.
Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Mofenson LM, Yogev R, Korelitz J, Bethel J, Krasinski K, Moye J Jr, Nugent R, Rigau-Perez JG. Mofenson LM, et al. Among authors: bethel j. Pediatr Infect Dis J. 1998 Oct;17(10):872-80. doi: 10.1097/00006454-199810000-00005. Pediatr Infect Dis J. 1998. PMID: 9802627
Serum vitamin A concentrations in a North American cohort of human immunodeficiency virus type 1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
Read JS, Bethel J, Harris DR, Meyer WA 3rd, Korelitz J, Mofenson LM, Moye J Jr, Pahwa S, Rich K, Nugent RP. Read JS, et al. Among authors: bethel j. Pediatr Infect Dis J. 1999 Feb;18(2):134-42. doi: 10.1097/00006454-199902000-00010. Pediatr Infect Dis J. 1999. PMID: 10048685
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.
Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, Moye J Jr, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ. Mofenson LM, et al. Among authors: bethel j. N Engl J Med. 1999 Aug 5;341(6):385-93. doi: 10.1056/NEJM199908053410601. N Engl J Med. 1999. PMID: 10432323 Free article. Clinical Trial.
210 results